(57 kDa) is the most ubiquituos intermediate filament protein and the first to be expressed during cell differentiation. All primitive cell types express vimentin but in most non-mesenchymal cells it is replaced by other intermediate filament proteins during differentiation. Vimentin is expressed in a wide variety of mesenchymal cell types - fibroblasts, endothelial cells etc., and in a number of other cell types derived from mesoderm, e.g., mesothelium and ovarian granulosa cells. In non-vascular smooth muscle cellsand striated muscle, vimentin is often replaced by desmin, however, during regeneration, vimentin is reexpressed. Cells of the lymfo-haemopoietic system (lymphocytes, macrophages etc.) also express vimentin, sometimes in scarce amounts. Vimentin is also found in mesoderm derived epithelia, e.g. kidney (Bowman capsule), endometrium and ovary (surface epithelium), in myoepithelial cells (breast, salivary and sweat glands), an in thyroid gland epithelium. In these cell types, as in mesothelial cells, vimentin is coexpressed with cytokeratin
Furthermore, vimentin is detected in many cells from the neural crest. Particularly melanocytes express abundant vimentin. In glial cells vimentin is coexpressed with glial filament acidic protein
Vimentin is present in many different neoplasms but is particulary expressed in those originated from mesenchymal cells. Sarcomas e.g., fibrosarcoma, malignt fibrous histiocytoma, angiosarcoma, and leio- and rhabdomyosarcoma, as well as lymphomas, malignant melanoma and schwannoma, are virtually always vimentin positive. Mesoderm derived carcinomas like renal cell carcinoma, adrenal cortical carcinoma and adenocarcinomas from endometrium and ovary usually express vimentin. Also thyroid carcinomas are vimentin positive. Any low differentiated carcinoma may express some vimentin.
Vimentin is frequently included in the so-called primary panel (together with CD45, cytokeratin, and S-100 protein). Intense staining reaction for vimentin without coexpression of other intermediate filament proteins is strongly suggestive of a mesenchymal tumour or malignant melanoma.
Entrez Gene (human): 10p13
The antibody VI-RE/1 reacts with human vimentin, a 57 kDa intermediate filament protein expressed on a wide variety of mesenchymal and mesodermal cell types.
- Flow Cytometry
Recommended dilution:1-10 μg/ml
- Western Blotting
Recommended dilution: 1-2 μg/ml, overnight in 4°C
Positive control: LEP-19 cell lysate
Negative control: 3T3 mouse cell line
Sample preparation: Resuspend approx. 50 mil. cells in 1 ml cold Lysis buffer (1% laurylmaltoside in 20 mM Tris/Cl, 100 mM NaCl pH 8.2, 50 mM NaF including Protease inhibitor Cocktail). Incubate 60 min on ice. Centrifuge to remove cell debris. Mix lysate with reducing Laemmli SDS-PAGE sample buffer. Boil for 3 min in water bath.
Application note: Reducing conditions. SDS-PAGE (10% separating gel).
Purified Antibody: 5-10 μg/ml
The antibody VI-RE/1 recognizes different epitope on human vimentin than the antibody VI-01 (IgM).
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.
Product Specific References
*Chen YK, Chang WS, Wu IC, Li LH, Yang SF, Chen JY, Hsu MC, Chen SH, Wu DC, Lee JM, Huang CH, Goan YG, Chou SH, Huang CT, Wu MT: Molecular characterization of invasive subpopulations from an esophageal squamous cell carcinoma cell line. Anticancer Res. 2010 Mar;30(3):727-36.
For research use only. Not for drug, diagnostic or other use.